Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2006 1
2007 5
2008 8
2009 3
2010 8
2011 6
2012 5
2013 15
2014 15
2015 20
2016 21
2017 21
2018 15
2019 18
2020 17
2021 16
2022 10
2023 11
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network.
Merseburger AS, Bakshi G, Chen DY, Chiong E, Jabbour M, Joung JY, Lai AY, Lawrentschuk N, Le TA, Ng CF, Ng CT, Ong TA, Pang JS, Rabah DM, Ragavan N, Sase K, Suzuki H, Teo MMH, Uemura H, Woo HH. Merseburger AS, et al. Among authors: joung jy. World J Urol. 2024 Mar 14;42(1):156. doi: 10.1007/s00345-024-04852-2. World J Urol. 2024. PMID: 38483562 Free PMC article. Review.
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Fizazi K, et al. Among authors: joung jy. Nat Med. 2024 Jan 31. doi: 10.1038/s41591-024-02835-9. Online ahead of print. Nat Med. 2024. PMID: 38297094 No abstract available.
Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer.
Park DJ, Kwon TG, Park JY, Joung JY, Ha HK, Jeon SS, Hong SH, Park S, Lee SH, Cho JS, Park SW, Kwon SY, Jo JK, Park HS, Lee SC, Kwon DD, Kim SI, Park SH, Kim S, Jeong CW, Kwak C, Choi SH; Korean Urologic Oncology Society Prostate Cancer Group. Park DJ, et al. Among authors: joung jy. World J Mens Health. 2024 Jan 2. doi: 10.5534/wjmh.230104. Online ahead of print. World J Mens Health. 2024. PMID: 38164028 Free article.
Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus without Confirmatory Bone Scan.
Jeong CW, Han JH, Kwon DD, Joung JY, Kim CS, Ahn H, Hong JH, Kim TH, Chung BH, Jeon SS, Kang M, Hong SK, Jung TY, Park SW, Yun SJ, Lee JY, Lee SH, Kang SH, Kwak C. Jeong CW, et al. Among authors: joung jy. Cancer Res Treat. 2024 Apr;56(2):634-641. doi: 10.4143/crt.2023.848. Epub 2023 Dec 5. Cancer Res Treat. 2024. PMID: 38062708 Free PMC article.
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Fizazi K, et al. Among authors: joung jy. Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4. Nat Med. 2024. PMID: 38049622 Free PMC article. Clinical Trial.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Saad F, et al. Among authors: joung jy. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. Lancet Oncol. 2023. PMID: 37714168 Clinical Trial.
193 results